Piotr Wysocki: Bone Pain and Survival Among Patients With mHSPC
Piotr Wysocki recently posted on LinkedIn:
“Bone pain is linked to worse overall survival (OS) in castration-resistant prostate cancer. However, its impact on survival in metastatic, hormone-sensitive prostate cancer (mHSPC) is not well recognized. A GETUG-15 study evaluating the addition of docetaxel to ADT revealed that baseline pain was an adverse prognostic factor regarding overall survival (OS).
Gabrael G et al. conducted a post hoc secondary analysis of the SWOG-1216 trial, randomized (1:1) 1279 newly diagnosed mHSPC patients to receive either androgen deprivation therapy (ADT) with orteronel or ADT with bicalutamide. The analysis included 1197 intention-to-treat patients with available bone pain status, of whom 25% had baseline bone pain, and 75% reported no bone pain.
Results:
Patients with bone pain were younger and had more high-volume disease.
Median PFS was 1.3 years (bone pain) and 3.7 years (no bone pain) – adjusted HR=1.46; P < .001.
Median OS: 3.9 years (bone pain) and Not reached (no bone pain) – adjusted HR for OS: 1.66; P < .001.
The post hoc analysis of the SWOG-1216 trial demonstrates that baseline bone pain in patients diagnosed with mHSPC represents an adverse prognostic factor in terms of both PFS and OS. This factor should be considered during initial treatment decisions, and I would discuss intensifying systemic treatment (ADT+abiraterone/darolutamide+docetaxel) in chemo-fit mHPSC patients with low-volume disease with accompanying bone pain.”
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer
Authors: Georges Gebrael, Yeonjung Jo, Umang Swami, Melissa Plets, Chadi Hage Chehade, Arshit Narang, Shilpa Gupta, Zin W. Myint, Nicolas Sayegh, Catherine M. Tangen, Maha Hussain, Tanya Dorff, Primo N. Lara Jr, Seth P. Lerner, Ian Thompson and Neeraj Agarwal.
Source: Piotr Wysocki/LinkedIn
Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.
His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.
Read other posts by Piotr Wysocki published on OncoDaily.
